-
Mashup Score: 1ESMO East 2023: Updates in Prostate Cancer with Dr Bruno Bastos - 3 month(s) ago
Presentation by Bruno Bastos, MD, Miami Cancer Center At the 2023 ESMO East review conference presented by Total Health in Fort Lauderdale, Florida, Dr Bruno Bastos from Miami Cancer Institute presented updates in prostate cancer from this year’s European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain. The abstracts selected featured new developments for targeted therapies in prostate cancer, including Lutetium (177Lu-PSMA-617), a type of targeted radiotherapy treatment for
Source: www.totalhealthoncology.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Looking at Novel Treatments in Lung and Genitourinary Cancers From ESMO 2023: Drs Janne and Bastos - 6 month(s) ago
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet-
Looking at Novel Treatments in Lung and Genitourinary Cancers From ESMO 2023: Drs Janne and Bastos https://t.co/wGpE7AIHwW via @onclive
-
-
Mashup Score: 1Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695) - 7 month(s) ago
In this phase 2 study, the COXEN predictive biomarker approach was applied to patients with muscle-invasive bladder cancer who were randomized to neoadjuvant gemcitabine-cisplatin (GC) or dose-dense methotrexate-vinblastine-adriamycin-cisplatin (ddMVAC). The GC COXEN score appeared to be prognostic for survival, but did not predict responses. The trial provides prospective randomized data showing that pathologic response (
Source: www.europeanurology.comCategories: Latest Headlines, Oncologists1Tweet-
Glad to be part of this cooperative effort in updating long term outcomes of SWOG S1314. Pathological response post neo-adjuvant chemotherapy for Bladder Cancer has prognostic Value. (SWOG S1314; NCT02177695) - European Urology https://t.co/W1czFPpTwV
-
-
Mashup Score: 0PREDICT-RT Study for Patients with High-Risk Prostate Cancer - 7 month(s) ago
Dr. Paul Nguyen, Principal Investigator of the NRG-GU009 “PREDICT-RT” study discusses the details of the trial for patients with high-risk prostate cancer.
Source: www.youtube.comCategories: Latest Headlines, Oncologists1Tweet-
PREDICT-RT Study for Patients with High-Risk Prostate Cancer https://t.co/hEzPFjuFSa via @YouTube
-
-
Mashup Score: 1Thanks to Clinical Trial, Melanoma Patient is Now in Remission - 8 month(s) ago
After standard treatment options failed to arrest his metastatic melanoma, a clinical trial saved Oscar Izquierdo’s life – “a perfect example of the crucial …
Source: www.youtube.comCategories: Latest Headlines, Oncologists1Tweet-
In celebration of the #WorldCancerResearchDay Research Day I am pleased to share this amazing successful story of how clinical trials may help save lives and advance the science in the fight against cancer https://t.co/cdBeWMVbpb
-
-
Mashup Score: 1
Key opinion leaders on renal cell carcinoma management review first-line treatment options in the advanced clear cell disease space.
Source: www.onclive.comCategories: Latest Headlines, Oncologists1Tweet-
Overview of First-Line Combination Therapy in Advanced Clear Cell RCC https://t.co/B6CHZyGYAf via @onclive
-
-
Mashup Score: 0
Dr Bruno Bastos comments on the role of risk assessment and biomarkers in the treatment of oligometastatic disease in prostate cancer at the 2022 ESMO Florid…
Source: YouTubeCategories: Latest Headlines, Oncologists1Tweet-
Biomarkers and risk assessment in oligometatstatic disease: 2022 ESMO Fl... https://t.co/9DrvLfllEl via @YouTube
-
-
Mashup Score: 1Defining oligometastatic disease, and its impact on treatment in prostate cancer: 2022 ESMO Florida - 1 year(s) ago
Dr Bruno Bastos comments on the evolving concept of oligometastatic disease in prostate cancer and incorporating that into clinical practice at the 2022 ESMO…
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
Defining oligometastatic disease, and its impact on treatment in prostat... https://t.co/ksKN9OEOB4 via @YouTube
-
-
Mashup Score: 1SELLAS Life Sciences' GPS Combo Therapy Shows Overall Survival Of 18 Months In Pretreated Ovarian Cancer Patients - 2 year(s) ago
SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced confirmatory topline data from the final analysis of results from its Phase 1/2 trial of galinpepimut-S (GPS). The trial assessed GPS in combination with Merck & Co Inc’s (NYSE: MRK) Keytruda (pembrolizumab) for WT1(+) relapsed or refractory platinum-resistant advanced metastatic ovarian cancer. Median Overall Survival (OS) was 18.4 months…
Source: finance.yahoo.comCategories: Hem/Oncs, Latest HeadlinesTweet-
JUST IN: GPS, a WT-1 peptide cancer vaccine, in combination with Pembrolizumab appears to be synergistic in WT-1 positive platinum resistant resistant ovarian cancer. Potential for WT-1 positive tumors too. Link: https://t.co/hhwsOHkLhF @MiamiCancerInst https://t.co/VqI5qbsfPg https://t.co/t9u5Rx2eBv
-
-
Mashup Score: 2SUMMARY - OncLive/State of the Science Summit/Genitourinary Cancer/Coral Gables/May 18, 2022 - 2 year(s) ago
OncLive® State of the Science Summit: Disease State, Month Day, Year. Oncology live event features research and clinical advances in oncology.
Source: event.onclive.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Looking forward to hosting OncLive’s State of the Science Summit event on Genitourinary Cancer tonight in Miami with outstanding speakers from our MCI GU program. The event is free to attend. Food and drinks will be provided. Registration link: https://t.co/auHHp4xWgr https://t.co/MJtPO45zc2
-
Best of ESMO 2023. Prostate Cancer Update. Glad for this opportunity to review the data presented at ESMO. https://t.co/SYJypj2wEj